Aequus Pharmaceuticals Inc. (CVE:AQS – Get Free Report)’s stock price hit a new 52-week low on Tuesday . The company traded as low as C$0.01 and last traded at C$0.01, with a volume of 3000 shares. The stock had previously closed at C$0.01.
Aequus Pharmaceuticals Stock Down 50.0 %
The stock’s fifty day moving average is C$0.01 and its two-hundred day moving average is C$0.02. The company has a current ratio of 0.07, a quick ratio of 0.46 and a debt-to-equity ratio of 138.88. The company has a market capitalization of C$663,150.00, a PE ratio of -0.50 and a beta of -0.02.
About Aequus Pharmaceuticals
Aequus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. The company markets ZIMED PF, a preservative-free bimatoprost ophthalmic solution. It also develops a range of prescription-free dry eye products under the OPTASE name; and REV-0100 for the treatment of stargardt disease.
Featured Stories
- Five stocks we like better than Aequus Pharmaceuticals
- Are Penny Stocks a Good Fit for Your Portfolio?
- Top Tax-Efficient Investments to Maximize Your Wealth
- What is a Stock Market Index and How Do You Use Them?
- Stellantis Stock Falls as CEO Departs: What Investors Should Know
- Manufacturing Stocks Investing
- 2 Stock Picks for Year-End: 1 to Keep, 1 to Cut
Receive News & Ratings for Aequus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aequus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
